Modulators of Melanocortin Receptors for the Treatment of Depression and Anxiety

Case ID:
UA17-079
Invention:

This invention is the use of the melanocortin 5 receptor (MC5R) ligand to treat depressive and anxiety disorders. MC5R antagonism is the proposed mechanism of action.

 

Background:
Depression and anxiety often have similar treatment, but experiencing the full effects of current pharmacotherapy can range from weeks to months. Antidepressants and anxiolytics are associated with a number of side effects including an increased risk of suicidal thoughts in those taking antidepressants. Therefore, a novel pathway is needed for rapid onset with minimal side effects.

 

Applications:

  • Pharmaceutical companies

 

Advantages:

  • Provides a treatment for depressive and anxiety disorders

Status: issued U.S. patent #11,542,302

Patent Information:
Contact For More Information:
Laura Silva
Sr. Licensing Manager, COS
The University of Arizona
lauras@tla.arizona.edu
Lead Inventor(s):
Victor Hruby
Minying Cai
Keywords: